Firm and environmental influences on the mode and sequence of foreign research and development activities by Penner-Hahn, Joan Diane
Strategic Management Journal, Vol. 19, 149–168 (1998)
FIRM AND ENVIRONMENTAL INFLUENCES ON THE
MODE AND SEQUENCE OF FOREIGN RESEARCH
AND DEVELOPMENT ACTIVITIES
JOAN D. PENNER-HAHN*
University of Michigan Business School, Ann Arbor, Michigan, U.S.A.
This paper develops an explanation for the mode and sequence of entry that firms select for
their international research and development activities. The hypotheses are based on the
internalization and evolutionary theory perspectives. I first hypothesize that there is a sequence
to the mode of foreign research and development activities initiated. I then discuss two firm
capabilities and alternatives which might cause firms to omit parts of the sequence. The context
of the study is the foreign research and development activities of incumbents and recent entrants
to the Japanese pharmaceutical industry. The results indicate intriguing differences between
the motivations of established firms and new entrants in establishing foreign research and
development activities. 1998 John Wiley & Sons, Ltd.
Strat. Mgmt. J., Vol. 19, 149–168 (1998)
INTRODUCTION
There is increasing interest in the evolving role
of firms’ international research and development
(R&D) activities. While there has been much
descriptive work (De Meyer, 1992; Pearce and
Singh, 1992a), the phenomenon has received little
conceptual development. In particular, there is no
broad-based explanation for the mode of entry
that firms select for their international R&D
activities. This paper develops a model using
firm-level factors to explain the entry mode and
sequence of international R&D activities. I draw
on internalization and evolutionary theory per-
spectives to develop this model. I test the model’s
predications in the context of established and
recent entrant firms in the Japanese pharmaceu-
tical industry that have undertaken overseas
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research and development activities in the United
States and Europe.
While much has been written about the mode
of foreign market entry, past work has focused
primarily on the sale of goods and services. Even
the works which have focused on the inter-
nationalization of R&D have emphasized the
influence of overseas production on the decentral-
ization of R&D (Ronstadt, 1977; Pearce and
Singh, 1992b). These earlier studies have gener-
ally followed product life cycle theory as
developed by Vernon (1966). This theory main-
tains that multinational firms usually undertake
overseas R&D activities in order to adapt their
products and processes to local markets. This
perspective was perhaps appropriate for stable
industry environments, but it is less suited to
current environments in which firms face many
challenges that require competitive response.
These challenges include increasing foreign com-
petition and intensifying domestic competition. It
appears that firms in many industries now under-
take overseas R&D activities as a response to
increased competition in their home markets and
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throughout the world, rather than as a support
function for existing sales operations in a host
market. Hamel and Prahalad (1985) argue that
global strategy increasingly requires foreign
research presence. Bartlett and Ghoshal (1989)
have identified an innovation in multinational
corporations which they describe as a ‘globally
linked’ approach. In this approach, a firm iden-
tifies geographically dispersed sources of com-
petitive resources and then links them through its
activities in order to gain competitive advantages.
International R&D activities contribute such glob-
ally linked competitive advantages. A missing
piece of the literature, though, is a description of
the form the firms’ R&D activities take in order
to obtain the dispersed sources of competitive
ability.
BACKGROUND
A large body of work addresses foreign entry
mode. Although most of this research discusses
sales and production, some implications of the
arguments apply to research entry. This prior
research emphasizes that entry modes differ in
terms of the degree of control that a firm has
over its foreign activities. On the one hand,
wholly owned subsidiaries provide the firm with
substantial control of foreign operations. On the
other hand, collaborative ventures provide less
autonomous control by a firm. Two sets of
perspectives—internalization theory and evolu-
tionary theory—offer particularly relevant per-
spectives to explore the question of foreign
research entry.
Internalization theory focuses on ownership of
firm-specific advantages that firms can transfer to
another country for economic benefit.1 The theory
stresses intangible assets, such as firm knowledge
concerning technical or marketing activities
(Hennart, 1982; Dunning, 1988). According to
this view of foreign direct investment, firms with
higher degrees of intangible knowledge will
undertake entry modes that provide firms with
1 The intellectual origin of internalization theory can be traced
to Coase (1937). Scholars such as Hymer (1976) and Caves
(1971) provided fundamental contributions. Williamson
(1975) operationalized the theory as transaction cost eco-
nomics, while the work of Dunning (1973), Buckley and
Casson (1976), Teece (1976), Rugman (1981), Hennart
(1982), and others is instrumental in developing the theory.
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greater degrees of control. Transaction cost theory
(Williamson, 1975, 1985; Teece, 1976) offers
n overarching perspective for the internalization
view. Transaction cost analyses of foreign entry
modes argue that firms which use transaction-
specific assets for their foreign activities will
undertake entry modes that provide greater
degrees of control (Anderson and Gatignon, 1987;
Gatignon and Anderson, 1988; Hennart, 1991;
Kim and Hwang, 1992). The internalization view
emphasizes incentives to choose entry modes that
protect the value of a firm’s knowledge from
opportunistic behavior by a partner. While
undoubtedly a partial explanation for foreign R&
D entry modes, the opportunism perspective is
not an encompassing explanation for cases in
which firms undertake foreign research in order
to acquire new knowledge, rather than to apply
existing knowledge. The appropriability of new
knowledge clearly is a factor in such cases but
firms must consider how the entry mode will
affect their ability to learn, as well as how the
mode will protect the value of what the firm
l arns.
Evolutionary theory provides a complementary
view to internalization theory. In counterpoint to
the perspectives that emphasize protecting the
value of knowledge, Kogut (1988) and Kogut
and Zander (1993) explain entry modes in terms
of adding to the knowledge of the firm. They
argue that this is an evolutionary theory of the
multinational firm in that firms accumulate knowl-
edge over time by following sequential entry
processes that combine their domstic knowledge
with what they learn in foreign markets. In this
view, firms initially will tend to undertake lower
control activities until they learn enough to take
greater control of their foreign activities. At a
general level, evolutionary economic theory
(Nelson and Winter, 1982) encompasses Kogut
and Zander’s (1993) evolutionary arguments con-
cerning the choice and sequence of entry modes.
A fundamental tenet of the evolutionary eco-
nomics model is that firms’ preexisting organi-
zational routines strongly influence their actions.
These organizational routines form the basis of a
firm’s capabilities. Winter (1990: 283) identified
evolutionary theory’s emphasis as being on the
‘firm’s role as a repository of productive com-
petence.’ When faced with a need for new capa-
bilities, such as undertaking foreign research,
firms tend to search in ways that are compatible
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with their existing routines. Applying this view
to foreign R&D entry modes suggests that one
must consider both how a firm’s existing capabili-
ties and how its need for new capabilities influ-
ence the choice and sequence.
In this study, I draw on both the protection
and the learning perspectives to analyze firms’
foreign R&D entry modes. I categorize the
organizational choices for a firm that undertakes
foreign R&D into three basic types, including
sponsored research, collaborative research, and
controlled research. Sponsored research activities
are those in which a firm funds research at a
university or another firm for projects that do not
involve company research staff. Firms usually
target sponsored projects for discovery of a speci-
fic product or phenomenon, often with a specific
project duration. Collaborative research projects
involve the participation of a firm’s employees
in the foreign research activity, either through
relocation to the foreign site or through undertak-
ing dual tracks of research at home and abroad.
Firms may undertake collaborative projects with
either universities or other firms. I include joint
ventures in the collaborative category. Controlled
research activities are those for which the firm
establishes ownership. Controlled activities can
be the acquisition of a foreign facility or the
establishment of a new facility. In these instances,
the firm employs foreign researchers to work in
these facilities and may also transfer scientists
from its domestic operation to the foreign site.
This three-part typology includes one form of
wholly intrafirm activity and two forms of collab-
oration, where one collaboration mode involves
organizational participation and the other involves
only financial participation.
Each of the three forms of foreign research
has advantages and difficulties concerning protec-
tion and learning. Sponsored research generally
has the lowest cost and requires the least knowl-
edge of the local environment, but also will tend
to provide the least return because the firm may
learn the least and will be unable to protect all
the benefits of the research conducted on its
behalf (Hagedoorn, 1993; Harrigan, 1985). At the
other end of the continuum, controlled research
offers the greatest protection and the greatest
potential learning, but also requires the greatest
commitment of money and effort as well as the
greatest knowledge of the local environment in
order to realize the potential learning. Collabo-
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rative research, which lies between the market
and the firm, offers a mid-ground position in
terms of protection and learning.
I have excluded licensing from the typology
of entry modes for R&D. The primary reason is
that firms usually form licensing arrangements to
ell or obtain a specific product, rather than to
undertake R&D activities. A licensee generally
lacks control of spin-off opportunities because
licensors attach restrictive conditions on their sale
of technology, such as geographically or byprod-
uct application (Odagiri and Goto, 1993).
In summary, several theoretical perspectives
offer relevant arguments concerning international
R&D entry modes. Internalization theory stresses
the need to choose a mode that protects the
value of knowledge, while evolutionary theory
emphasizes the importance of obtaining new
knowledge. For the purpose of this paper, I have
categorized foreign research modes as sponsored,
collaborative, and controlled, which vary in terms
of protection and learning opportunities. In the
next section, I develop hypotheses regarding the
sequence of sponsored, collaborative, and con-
trolled research activities that firms will tend to
undertake outside their home country.
HYPOTHESES
The hypotheses address two primary issues. I
first discuss how sponsored, collaborative, and
controlled foreign research activities provide a
sequence of increasing intensity of commitment,
learning, and protection. I then discuss two factors
and alternatives that might cause firms to skip
parts of the sequence.
Firms have strong incentives to undertake con-
trolled research activities, due to both protection
and learning factors. Controlled research offers
greater protection for the value of research than
do sponsored or collaborative research. Moreover,
controlled research activities offer firms the great-
est opportunity to influence the ongoing direction
of research as new results unfold. If learning
about new environments is a major factor for
foreign research, however, many firms will be
unable to jump directly to controlled research
activities when they begin to undertake foreign
R&D because the dual burden of a new activity
and a new geographic locale would be too large.
I start by emphasizing the learning-based per-
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spective on initial international expansion. Firms
undertaking an international R&D activity are
interested in learning about the subject of the
specific research activity. In order to be effective
at this learning firms need to have some under-
standing of the nature of the research process as
well as the national context in which the research
takes place.
The learning perspective suggests that many
firms will follow a sequence of increasing inten-
sity in undertaking R&D activities abroad, instead
of initially undertaking controlled research. That
is, firms are likely to establish at least one spon-
sored research activity first, followed by one or
more collaborative projects which, in turn, are
followed by a controlled research activity. Stop-
ford and Wells (1972) argue that lack of
familiarity with a location will lead a firm to
undertake less controlled entry modes. According
to Mitchell, Shaver, and Yeung (1994), sequential
entry allows a firm to learn about its new environ-
ment gradually. Such a sequential expansion of a
firm’s activities after the initial entry into a coun-
try is ‘an expression of the evolutionary acqui-
sition and recombination of knowledge’ (Kogut
and Zander, 1993: 640). Only once a firm gains
substantial knowledge of the local environment
and begins to generate research results does the
need to protect the value of research dominate
the incentives to learn from locally based entities.
Sponsored research provides an initial step in
which firms begin to learn about the research
environment in a new country. Relevant issues
that a firm must learn before undertaking its own
research include scientific norms, the geographic
location of specific research capabilities, and the
strengths and weaknesses of specific research
institutions. The overarching issue is that each
country has its own national innovation system
that a firm must understand before it can under-
take deep learning concerning specific products
and processes (Nelson, 1993). Consistent with
this view, sponsoring foreign R&D can also be
thought of as an option that the firm might
exercise if the sponsored research develops valu-
able results (Arora and Gambardella, 1994).
The second stage in the sequence, collaborative
research, adds an organizational dimension to the
research activity. Once a firm learns enough about
the foreign research environment through spon-
sored research, it will often wish to undertake
hands-on research activity. The tacit nature of
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R&D means that companies will often need an
organizational presence in order to learn how to
do research in a particular scientific area. Only
by being involved can a firm gain a deep under-
standing of the strengths and weaknesses and
reas of opportunity that a technology offers
(Nelson and Rosenberg, 1993). Collaboration
with a firm or university in a foreign location
offers an initial means of undertaking hands-on
research in an environment that a firm under-
stands only imperfectly. The collaboration stage
also adds an organizational dimension to the
options perspective, in the sense that a firm may
need to undertake hands-on activity in order to
realize the value of its option for tacit technology.
That is, unlike a financial option in which a
buyer simply cashes in his or her valuable option,
a research option will often require that the firm
undertake direct participation in the next stage of
development if it wishes to realize the value of
the option.
Finally, controlled research requires the greatest
financial and managerial commitment of the three
modes (Hagedoorn, 1993), along with the greatest
knowledge of the local environment. I expect
many firms to undertake controlled research only
once they have gained a reasonable understanding
of the foreign research environment by first
undertaking sponsored and collaborative research.
That is, many firms will increase their level of
vestment and involvement in a foreign R&
D activity only as they learn more about the
environmental context, scientific viability, and
market potential of technological areas. Undertak-
ing controlled research will then provide the firm
with the ability to direct future development and
to protect the results of what the firm is learning
in the foreign location.
Hypothesis 1: Firms will tend to undertake
foreign R&D activities in a sequence of spon-
sored, collaborative, and controlled research
activities.
Although I expect that learning issues will lead
many firms to follow the sponsored, collaborative,
and controlled sequence of research activities, I
also expect that the existing possession of scien-
tific knowledge capabilities will influence some
firms to undertake activities out of sequence.
I focus on two types of scientific knowledge
capabilities: domestic research skills and comple-
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mentary technical skills. Both types of capabilities
are relevant to foreign research expansion. Dom-
estic research skills provide linkages to the tra-
ditional knowledge base of an industry, while
complementary technical skills provide linkages
to emerging technological opportunities. Together,
the two sets of capabilities are most relevant
in cases where an industry is faced with new
technological opportunities, while existing techno-
logical bases remain valuable. This context is true
of many industries, including the pharmaceutical
industry that is the focus of my empirical analy-
sis.
The possession of particularly strong domestic
R&D capabilities may influence firms to estab-
lished controlled foreign R&D activities out of
sequence. In part, this prediction draws from
learning issues. Firms which have strong domestic
research capabilities in the relevant market area
have a particularly deep understanding of the
tacit aspects of that research (Teece, 1976). The
presence of strong in-house research may allow
firms to be more effective at evaluating inter-
national research opportunities. Their experience
means that they may have skills required to be
directly involved in the research, through collabo-
ration or control, even though the research is
conducted in a new environment. Moreover, firms
with strong domestic research capabilities would
have the absorptive capacity required to transfer
knowledge from the foreign environment to their
domestic operations. Cohen and Levinthal (1990)
argue that firms with increased absorptive
capacity will tend to be proactive and exploit
opportunities present in the environment. Gambar-
della (1992) has shown that firms with better in-
house scientific research are more effective at
exploiting external scientific information. In
addition, a firm with strong R&D capabilities
would be likely to believe itself competent to
collaborate or manage such a facility anywhere
in the world due to a belief in the commonality
of the scientific community throughout the world.
The protection logic also applies here. Firms
with a well-developed R&D capability are likely
to have developed proprietary knowledge. Much
of the literature on entry mode has discussed the
hazards of transferring knowledge across organi-
zational boundaries. Stopford and Wells (1972),
Gatignon and Anderson (1988), and Gomes-
Casseres (1989) have shown that greater R&D
intensity leads to full ownership of subsidiaries
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in the case of U.S. firms. Thus, firms with a high
degree of R&D capability may also be worried
about reverse flow of information in the case of
a collaborative foreign R&D activity. This fear
of exposing their proprietary information could
drive firms to establish collaborative or controlled
activities, rather than risk leakage through spon-
sorships. For both learning and protection reasons,
therefore, I expect firms with strong domestic
r search capabilities to be most likely to establish
controlled foreign R&D facilities out of sequence.
Firms that possess strong complementary tech-
nical skills also may be likely to undertake for-
eign research activities out of sequence. Com-
plementary technical skills consist of
technological knowledge in fields closely related
to the scientific area that a firm might explore
through an international R&D activity. A firm
which judges itself to possess relevant technical
skills may believe that it knows enough to estab-
lish collaborative or controlled foreign R&D
activities without first sponsoring foreign research
activity. Strength in a particular process skill
may drive firms to seek products that utilize that
process. Teece (1986) argues that firms which
already control the specialized complementary
assets necessary for commercialization of a tech-
nology will be able to maximize their return on
their R&D investment. Teece (1986) recommends
that firms target technology areas for which they
already control the specialized complementary
assets necessary for commercialization of the
technology. Firms targeting particular technology
areas in order to acquire products would need to
be certain of being able to protect the value of
research, which would be more assured through
the establishment of a collaborative or controlled
research activity than through sponsorship.
Hypothesis 2: The greater a firm’s scientific
knowledge capabilities in the relevant market
area, the more likely the firm is to undertake
a foreign collaborative or controlled research
activity before undertaking a sponsored
research activity.
There are alternative explanations for disruption
of the sequence of entry mode. One factor which
could disrupt the sequence is the timing of the
firm’s initial R&D activity. Another factor which
could disrupt the sequence is the firm’s preexist-
ing knowledge of the foreign market. Either of
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these factors could influence firms to undertake
international R&D activities out of sequence.
The time that a firm first undertakes foreign
R&D activities may affect the sequence of
research modes. In almost all industries in eco-
nomically developed countries, several national
competitors might engage in foreign R&D. If a
firm is among the first of the national firms
within an industry to undertake foreign R&D,
which I refer to as an early entrant, it may be
more likely to follow the sequence of sponsored,
collaborative, and controlled. However, the later
a firm is to undertake its first international R&D
activity, relative to its national competitors, the
more likely the firm will start at a later point in
the sequence of entry. There are two reasons for
this disruption of the sequence of entry. The first
reason is that a later entrant will have the advan-
tage of learning from its predecessors (Mitchell
et al., 1994), which is the result of spillovers
from previous entrants (Shaver, 1994). Later
entrants also might feel more competitive pressure
to establish international R&D activities due to
issues of competition, legitimacy, and imitation,
creating a bandwagon effect in which firms rush
to undertake hands-on international research
activities (Knickerbocker, 1973; Graham, 1978).
These later firms see that the earlier entrants have
progressed to collaborative or even controlled
research activities and may believe it necessary
to establish international R&D activities that are
further along in the sequence in order to remain
competitive in the industry. Later entering firms
may feel the need to expand internationally most
intensely where competition in their home market
is increasing (Graham, 1990).
Firms with previous foreign market knowledge
might establish collaborative or controlled R&D
activities earlier than sponsored activities. Firms
obtain foreign market knowledge by participating
in the market through a sales subsidiary or export
activity (Ronstadt, 1977). Such firms might per-
ceive their specific market knowledge as lessening
the barriers to foreign R&D.
In summary, the hypotheses address the
sequence of entry mode for foreign research
activities. Hypothesis 1 predicts a common
sequence of sponsored, collaborative, and con-
trolled activities. Hypothesis 2 argues that firms
with strong scientific knowledge capabilities will
often expand out of sequence. Alternative expla-
nations argue that the timing of the firm’s entry
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into international R&D or the firm’s market
knowledge will induce the firm to expand their
activities out of sequence. I now turn to the
empirical context of the study.
THE INDUSTRY CONTEXT
I chose the Japanese pharmaceutical industry to
test the hypotheses. The use of a single industry
and country allows a detailed understanding of
the companies involved in the industry. Firms in
the pharmaceutical industry depend on intensive
R&D activities in order to maintain competi-
tiveness as do firms in industries like electronics,
chemicals, communications, and aircraft manufac-
ture.
Pharmaceuticals is considered a high-
technology industry. For example, U.S. pharma-
ceutical companies spent an average of 16 percent
of sales on R&D early in the 1990s (Japanese
Pharmaceutical Manufacturers Association, 1992).
The pharmaceutical industry also has recently
experienced substantial change in its R&D activi-
ties due to the increasing applicability of biotech-
nology. This technological change has necessi-
tated the acquisition of new research skills by
pharmaceutical firms. These skills can be acquired
in several ways: through sponsored research, col-
laboration such as joint ventures, or through
establishment of wholly owned research facilities.
Therefore, the pharmaceutical industry provides
many of the triggers for international research
and an ideal opportunity to test the hypotheses I
developed above.
The Japanese pharmaceutical industry is the
specific context in which I test the hypotheses.
In addition to enjoying the general features of
the pharmaceutical industry, the Japanese pharma-
ceutical industry only recently experienced pres-
sures to expand abroad. The Japanese domestic
pharmaceutical market is the second largest sin-
gle-country market in the world after the United
States. The size of this market meant that
Japanese pharmaceutical firms generally did not
feel pressure to expand abroad until the 1980s.
At that time, the pressure in the domestic market
i creased due to two factors (Reich, 1990; Mitch-
ell, Roehl, and Slattery, 1995). First, government
restrictions on the entry of foreign firms began
to be lifted during the late 1970s. Second, the
government introduced price controls for pharma-
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ceuticals starting in the 1980s in order to decrease
national expenditures on health. The government
allocated higher prices to newer drugs in order
to encourage pharmaceutical innovation. These
two factors placed pressure on pharmaceutical
firms to seek markets and technology outside
Japan starting in the early 1980s.
In addition to the recent beginning of inter-
nationalization of the Japanese pharmaceutical
industry, the number of firms in the industry
makes this empirical context appropriate for my
study. The industry is neither too concentrated
nor extremely diffuse. The top four domestic
firms accounted for 25 percent of sales in the
Japanese market in 1991. The top 31 domestic
firms, by sales revenue, accounted for 70 percent
of sales in 1980 and 85 percent of sales in 1991.
Complementary technical skills are relevant in
the empirical context of the Japanese pharmaceu-
tical industry because biotechnological develop-
ments have affected the firms’ R&D environment.
During the 1960s and 1970s, several molecular
biology discoveries changed the nature of drug
discovery for all pharmaceutical firms. Previously,
firms had experimented with compounds that they
hoped would have a desired physiological effect.
Large groups of organic chemists synthesized
minor variants on a common root structure, which
required the testing of hundreds of compounds in
order to discover the most effective compound.
With biotechnological techniques, a therapeutic
protein can be synthesized through the manipu-
lation of genetic structure of cells. The technical
skills required for synthesizing compounds
through biotechnology are very different from the
chemical methods that had previously been used
(Pisano, 1990).
Biotechnology represents a radical change in
the technological environment of established
pharmaceutical firms. Nonetheless, biotechnology
has conflicting effects on the traditional skills of
pharmaceutical firms. In Tushman and Anderson’s
(1986) terminology, biotechnology is ‘com-
petence destroying’ in terms of R&D capabilities.
By contrast, however, biotechnology is ‘com-
petence enhancing’ in terms of commercialization
capabilities, because biotechnology can be used
to develop a myriad of products which can be
sold through the usual pharmaceutical channels
(Mitchell, 1989). The enhancement of commer-
cialization capabilities provides strong incentives
for established pharmaceutical companies to
undertake biotechnology research.
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Japanese firms faced strong incentives to under-
take international research if they wished to
develop biotechnology-based skills. Although
many Japanese firms had strong capabilities in
processes that are relevant to biotechnology, such
as fermentation, most of the early product
advances occurred outside Japan. Scientists work-
ing in Great Britain provided the intellectual
development of molecular biology (Nelson,
1993). Researchers in the United States have
undertaken much subsequent work in biotechnol-
ogy (National Research Council, 1992). Both
countries continue to be leaders in the field of
biotechnology. Thus, Japanese firms wishing to
obtain competence in biotechnology needed to
seek expertise abroad, especially in the United
States and Western Europe. Moreover, because
the primary locations of the knowledge were
stable countries, the firms could chose entry
modes independent of any issues of country risk
(Vernon, 1985; Kobrin, 1982). Instead, differ-
ences in the firms’ capabilities are more likely to
explain differences in modes.
The development of biotechnology also
expands the empirical base for the study, by
raising the distinction between established
Japanese pharmaceutical companies and recent
entrants to the industry. The possibilities of
biotechnology have induced a number of other
players to enter the pharmaceutical market. In
Japan, textile, food, brewing, and even steel com-
panies entered the pharmaceutical industry during
the 1970s and early 1980s and started exploring
biotechnology, often undertaking research outside
Japan. For some of these diversifying companies,
ntry to the pharmaceutical industry represented
an extension of their skills with fermentation,
which is the process by which many biotechnol-
ogical products are produced (Watanabe, 1986).
The food and brewing companies have a long
experience in fermentation through the production
of sake, beer, and other alcohol products. For
other recent entrants, without fermentation skills,
biotechnology is a technological tool for diversi-
fication into new, higher value-added product
areas (National Research Council, 1992).
Although biotechnology has applications in many
sectors, including agriculture, industrial chemi-
cals, electronics, energy, and environmental treat-
ment, health care is by far the largest market
egment for biotechnology applications. There-
f re, the relevant sample for the study includes
both the established Japanese pharmaceutical
156 J. D. Penner-Hahn
companies and many recent entrants to the indus-
try.
In summary, the Japanese pharmaceutical
industry provides an appropriate context for test-
ing hypotheses related to the internationalization
of R&D for four reasons. First, the pharmaceu-
tical industry is a high-technology industry that
depends heavily on the outcome of R&D activi-
ties. Second, Japanese pharmaceutical firms faced
increasing pressures during the 1980s to become
globally competitive, which both provides an
opportunity for the study and limits the relevant
time frame. Third, the Japanese pharmaceutical
industry is sufficiently diffuse to provide a large
enough sample for this study. Fourth, recent
changes in the technology necessary for pharma-
ceutical discovery requires a response from firms
involved in the industry and create incentives for
new firms to enter the industry. The combination
of increasing competition and a changing tech-
nology base is a powerful incentive for firms to
reach out for technology outside national borders.
This work explores the question of how the incen-
tives affected the international research entry
mode choices of different firms.
I believe that the framework I have developed
can help explain the actions of firms from other
countries and industries. Using the Japanese
pharmaceutical industry as a research context may
seem to limit the generalizability of the research.
However, most of the previous research on inter-
nationalization has focused on the actions of the
U.S. firms (Sakakibara and Westney, 1992). It
may be that it is the U.S. context which is unique
and that the Japanese case is more similar to that
experienced by European firms due to their simi-
lar market sizes and other factors such as techno-
logical capabilities (Reed, 1993). Certainly, many
Japanese and European firms are pursuing inter-
nationalization of R&D. Over 50 percent of the
250 foreign-owned R&D facilities in the United
States at the end of 1992 were established in the
last 5 years. R&D spending by foreign-owned
companies in the United States nearly doubled
between 1987 and 1990, increasing from $6.5
billion to $11.3 billion (Serapio and Dalton,
1993). This included 250 R&D facilities owned
by 100 foreign parent companies from Japan,
Germany, Britain, France, and South Korea.
Japanese firms are certainly appropriate objects
of study since they have led this trend, accounting
for 60 percent of these activities. In addition,
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pharmaceutical firms from many countries have
invested in R&D in the United States. The
majority of the European research activities in the
United States have been focused on biotechnology
(63% of 95 facilities). While these activities may
be a small fraction of the total R&D spending in
he United States, the phenomenon clearly has
growing importance. I expect this framework to
be generalizable to other industry and country
contexts.
METHODS
This section includes descriptions of the sample,
data sources, variable definitions, and statistical
methods I use to test the hypotheses.
Sample and data sources
I collected the data on firms involved in the
Japanese pharmaceutical industry for the time
period 1980–92 (Penner-Hahn, 1995). The year
1980 is an appropriate starting point for the study
since that is the beginning of a period of substan-
tial technical, regulatory, and competitive change
for the Japanese pharmaceutical industry. Tar-
g ted firms include the top 31 domestic Japanese
pharmaceutical firms by sales in 1980, together
with 35 recent entrants to the Japanese pharma-
ceutical industry. I exclude European and U.S.
pharmaceutical firm subsidiaries with Japanese
pharmaceutical sales from the sample. I planned
to include the top 30 firms in the sample but
settled on 31 firms because the 30th and 31st
firms had about the same sales. The 31 firms in
the sample account for 85 percent of pharmaceu-
tical sales in Japan in 1991. The firms that are
included are the major ethical pharmaceutical
manufacturers in Japan. Of the 31 pharmaceutical
firms included in the study, 20 established at
least one foreign R&D activity during the study
period. To my knowledge, the sample includes
all of the foreign pharmaceutical R&D activities
undertaken by Japanese firms during this period.
I selected recent entrants to the pharmaceutical
industry on the basis of industry analyses by
Yano Keizai Research Institute, Toyo Keizai, the
Pharmaceutical Industry Forum, and others which
indicated that these firms had either started
pharmaceutical research or had pharmaceutical
products for sale. The new entrants include tex-
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Table 1. Year of establishment of initial foreign R&D activity for pharmaceutical and new entrant firms
Pharmaceutical firms New entrant firms
1980 Green Cross (cn)
1981 Toray (sp)
1982 Daiichi (sp) Kirin (co)
Kyowa Hakko (sp)
Otsuka (cn)
Shionogi (co)
Yamanouchi (co)
Yoshitomi (sp)
1983 Fujisawa (co)
1984 Tanabe (co) Suntory (sp)
1986 Takeda (co) Asahi Breweries (sp)
Nitto Boseki (cn)
1987 Chugai (sp) Mitsubishi Kasei (sp)
Eisai (cn) Nissin Foods (cn)
Snow Brand (co)
Teijin (sp)
1988 Meiji Seika (co) Ajinomoto (sp)
Morinaga Milk (sp)
NKK (sp)
1989 Dainippon (co) Hitachi Chemical (sp)
Ono (co) Shiseido (sp)
SSPharmaceutical (co)
Sumitomo Seiyaku (sp)
Taiho (cn)
1990 Sankyo (cn) Japan Tobacco (sp)
1991 Mochida (co) Kanebo (co)
Nippon Mining (co)
(sp) indicates a sponsored activity; (co) indicates a collaborative activity; (cn) indicates a controlled activity.
tile, food, beverage, chemical, and steel firms.
Most of these firms entered the pharmaceutical
industry during the 1970s, although most intro-
duced their first products only recently. In a
survey of these recent entrants, Tanaka (1992)
found that the majority of the companies iden-
tified application of technology as a main motive
for entering the pharmaceutical industry. Seven-
teen of the 35 recent entrant firms had established
at least one foreign R&D activity by the end of
the study period. The sample includes all recent
entrants to the Japanese pharmaceutical industry
that I was able to identify through the multiple
sources I consulted.
I consider the established pharmaceutical firms
and recent entrants separately in my analysis. The
firms in the two groups are likely to possess
very different capabilities and objectives. The
established pharmaceutical firms are the tra-
ditional pharmaceutical firms, which we would
expect to be stronger in drug development skills.
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Some, but not all, of the pharmaceutical firms
have strength in fermentation given their involve-
ment in the production of antibiotics. We would
expect some of the new entrant firms to have
strong skills in fermentation given their historic
involvement in liquor, soy sauce or milk products.
The new entrant firms would be less likely to
have skills in drug development given that the
pharmaceutical industry is a relatively new area
of activity for them. Many other differences
between the two groups of firms will influence
heir efforts to establish foreign R&D activities.
The pharmaceutical firms are generally smaller
than the new entrants, which tend to be large
diversified firms. Almost all the pharmaceutical
firms are one-industry firms while, by contrast,
most recent entrants are large diversified firms.
The new entrants to the pharmaceutical industry
have very different motivations for their R&D
activities when compared to the traditional
pharmaceutical firms. New entrants, which are
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entering a new industry, are seeking diversifi-
cation opportunities through their pharmaceutical
activities. The established firms are familiar with
the pharmaceutical industry and are defending
their pharmaceutical position. The pharmaceutical
firms are familiar with the industry, while the
new entrants must learn about the industry while
also learning about new R&D areas. Although
some of these differences can be measured
directly, many differences are impossible to cap-
ture directly. Therefore, I have considered the
two groups separately in my analysis.
I collected data for this study from several
sources. The principal sources for information
concerning entry and motivation are interviews
with selected Japanese pharmaceutical firms
regarding their foreign R&D activities and a sur-
vey sent to the remaining members of the sample.
The interviews took place in Japan during May
and June of 1993. At that time, a team of
researchers interviewed 15 Japanese established
and recent entrant pharmaceutical firms. In most
cases, the company employees we interviewed
were members of the R&D strategy staff or the
equivalent. Prior to the interviews, we sent the
firms summaries of their foreign R&D activity,
which we obtained from public sources. The
interviewers verified the accuracy of the activity
reports and obtained information on any missing
activities. The interviews also provided the study
team with information regarding the companies’
R&D strategies and general philosophies.
I sent the remaining Japanese established and
recent entrant pharmaceutical firms a summary of
their foreign R&D activities, again obtained from
public sources, and asked for confirmation of
these activities. The archival search resulted in a
data base of approximately 115 foreign R&D
activities undertaken by the firms in the sample.
I sent the summary and request for confirmation
to the Vice President for Pharmaceutical Research
and Development at each firm. I contacted the
established pharmaceutical firms through their
representative with the Japanese Pharmaceutical
Manufacturers Association (JPMA). I contacted
the recent entrant firms using the address provided
in the Japan Company Handbook. The publi-
cationJapanese Overseas Investment: A Complete
Listing by Firms and Countries 1992/93was the
primary source of information on the firms’ for-
eign R&D activities. I supplemented the infor-
mation obtained through the interviews and sur-
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veys with secondary data from industry guides,
industry research studies, government reports,
corporate annual reports, and on-line data bases.
The industry guides used include theJapan Com-
pany Handbookand the Japan Pharmaceutical
Manufacturers’Data Book 1992. LEXIS/NEXIS
was the primary data base used to obtain business
articles from international newspapers and jour-
nals.
Variables and statistical methods
The dependent variable for this study is a measure
of the mode of foreign R&D activity that was
initiated by an individual firm during the period
1980–92. No firms began foreign research activi-
ties before this period. I categorized the foreign
R&D activities as sponsored, collaborative, or
controlled based on their characteristics as
described previously. For the purposes of this
study, I defined R&D as any activities needed to
ynthesize, formulate, and test a pharmaceutical
product prior to human clinical trials. I excluded
clinical activity undertaken for the purposes of
conducting human trials from the analysis,
because this type of activity is generally focused
on preparing a specific drug for a particular mar-
ket. Human clinical trial activity is thus much
closer to a marketing activity than a research
activity. In addition, the motivation for human
clinical trials is more one of complying with
government regulations rather than acquiring new
knowledge. This study focused on the acquisition
knowledge which would aid in the creation of
new pharmaceuticals.
I defined independent variables for scientific
knowledge capability as domestic research capa-
bility measured by drug patents or complementary
technical skills measured by fermentation patents
to test Hypothesis 2. Table 2 reports summary sta-
tistics.
I based the measures of domestic research
capability and complementary technical skills on
p tent classifications taken from the U.S. patents
granted to each firm. Patent examiners at the
U.S. Patent and Trademark Office assign patent
classes. The examiners assign each patent a pri-
mary patent class and subclass, based on the
information that the patent applicant provides.
Technological and functional principles are the
primary basis for patent classes, rather than prod-
ucts and industries, which makes patent classes
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Table 2. Correlation matrix and descriptive statistics
Sponsored Collaborative Controlled Drug Fermentation Foreign sales Entry R&D avg. Export Size Age
Variables patents patents offices expenditure ratio
Pharmaceutical firms(N = 20)
Sponsored 1.00 −0.58 −0.33 0.22 0.02 0.06 −0.21 0.24 0.55 0.28 0.28
Collaborative 1.00 −0.58 −0.11 0.22 0.10 0.19 −0.06 −0.18 −0.10 −0.47
Controlled 1.00 −0.10 −0.28 −0.18 −0.01 −0.17 −0.33 −0.16 0.27
Drug patents 1.00 0.49 0.45 0.12 0.97 0.38 0.95 0.28
Fermentation patents 1.00 0.70 0.01 0.51 0.53 0.58−0.16
Foreign sales offices 1.00 −0.20 0.46 0.45 0.59 0.16
Entry year 1.00 0.08 −0.16 0.14 −0.05
R&D avg. expenditure 1.00 0.43 0.95 0.25
Export ratio 1.00 0.50 0.05
Size 1.00 0.33
Age 1.00
Descriptive statistics
Mean 0.25 0.50 0.25 25.15 9.40 0.35 1986 7018.40 3.85 131,399 19 37
S.D. 0.44 0.51 0.44 27.60 10.21 0.49 3.51 7205.00 3.63 155,477 20.22
New entrant firms(N = 17)
Sponsored 1.00 −0.75 −0.49 0.23 0.21 0.13 −0.05 0.32 0.18 0.20 0.12
Collaborative 1.00 −0.20 −0.12 −0.13 −0.10 0.12 −0.18 −0.13 −0.01 −0.12
Controlled 1.00 −0.18 −0.14 −0.07 −0.10 −0.23 −0.10 −0.28 −0.02
Drug patents 1.00 0.33 −0.12 0.08 0.06 0.14 −0.08 0.06
Fermentation patents 1.00 0.15 −0.01 0.00 −0.01 −0.09 −0.15
Foreign sales offices 1.00 −0.22 0.44 0.36 −0.20 −0.47
Entry year 1.00 −0.33 −0.02 0.15 0.47
R&D avg. expenditure 1.00 0.88 0.10 −0.49
Export ratio 1.00 0.01 −0.40
Size 1.00 0.30
Age 1.00
Descriptive statistics
Mean 0.65 0.24 0.12 7.59 5.41 0.59 19 87 2633.24 8.82 600,109 19 37
S.D. 0.49 0.44 0.33 15.95 13.56 0.51 2.65 3707.32 10.54 663,435 20.14
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useful for measuring a firm’s technical skills.
Griliches suggests that ‘it is possible to use a
firm’s distribution of patenting by field to infer its
position in “technological space” ’ (1990: 1702).
Jaffe (1986) grouped 328 patent classes into 49
categories, with which he then characterized the
technological positions of the firms.
I measured the firms’ domestic research com-
petence by the number of patents categorized in
the two drug classes of 424 and 514. The link
between drug patents and research capability is
quite direct, as one would expect that competence
in R&D would result in patents for new drugs.
Complications arise in the counting process
because patents have multiple patent classes
assigned to them, while a particular patent may
use a single patent class more than once when
combined with different subcategories. For each
patent in this study, I counted a class only once
regardless of the number of times it appeared.
Similarly, I counted patents that appeared in both
drug classes 424 and 514 only once. I based the
counts on the patent class assigned to each patent
received by the firms during the 1975–80 period.
This time period is appropriate because the objec-
tive is to capture a measure of the skills possessed
by the firms prior to the study period.
I used the count for the patent class for Mo-
lecular Biology and Biochemistry (435) to meas-
ure complementary technical skills. This patent
class is of particular interest as it includes all
patents related to fermentation. This study defines
fermentation as a complementary technical skill
due to its importance to the production of many
biotechnological products (Pisano, 1990). In the
cases where the Patent Office classified a patent
in both a Drug classification (424 or 514) and
the Molecular Biology (435) classification, I
counted the patent only in the Molecular Biology
classification. This affected 60 of the 1040 patents
included in the study. A sensitivity analysis that
counted the patents in both categories did not
alter the results reported.
The CASSIS data base from the Patent and
Trademark Office of the U.S. Department of
Commerce contains the information of patent
classes. The data base is available on compact
disk in depository libraries around the United
States. I copied the patents for each of the com-
panies in the sample to disk and then used a
Fortran program to obtain the patent classes for
each of the patents.
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Using U.S. patents to measure the technical
skills of Japanese firms is appropriate because
Japanese firms as well as firms of other national-
ities systematically patent in the U.S. system.
Japanese firms had the second largest percentage
of U.S. patents granted, after U.S. firms, in 1986
(Wineberg, 1988). The United States represents
the largest single market in the world for pharma-
ceutical products, so that most firms want to
protect their rights with U.S. patents. In addition,
the Japanese system is slow to grant patents, with
5–7 years median wait as opposed to 2–3 years
in the United States (Dunphy, 1988). This pro-
vides even more incentive for Japanese firms to
patent their drug discoveries in the United States.
One firm in the sample had over 450 U.S. patents
granted during the period studied. In addition, the
pharmaceutical industry is one in which patents
play an extremely important role in protecting
the intellectual capital of firms. In this industry,
more so than in many others, firms are likely to
apply for patents when there is a development
which may lead to a future product.
I define other variables to examine alternative
explanations of disruptions to the sequence of
R&D activities. These other variables include
entry timing and foreign market knowledge meas-
ured by foreign sales offices and export ratios. I
used the number of years after 1979 that a firm
undertook its first foreign research activity as the
entry timing variable. The first firm undertook its
first activity in 1980. The last firm to begin
foreign research in the sample initiated its
research activity during 1991. I measured foreign
market presence by whether a firm had a foreign
sales office at the start of the study period, that
is, prior to 1980. I collected this information
from Japanese Overseas Investment: A Complete
Listing by Firms and Countries 1992/1993. The
purpose of the foreign sales office variable is to
determine whether the prediction that R&D activi-
ties tend to follow marketing activities (Ronstadt,
1977), based on product life cycle theory, pro-
vides greater explanatory power than the research
competence and competitive pressure predictions
of this study. The variable will also help assess
whether marketing activities provide sufficient
environmental knowledge to allow firms to skip
early stages in the research activity sequence.
Where possible, I also recorded the firm’s export
sales ratio in 1980, which correlates moderately
strongly with foreign sales offices.
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In addition, I recorded several supplemental
variables in order to gain information about the
firms. I took the values of these supplemental
variables from the beginning of the study period
in order to avoid endogeneity with foreign
research activities and because the values of most
variables change only slightly from year to year
during the study period. I measured average
annual R&D expenditure, which correlated highly
with drug patents for the established pharmaceu-
tical firms. I measured firm size, based on sales
revenue, which also correlated highly with drug
patents. Finally, I measured firm age in years,
which had moderate correlation with patents and
size, especially among the established pharmaceu-
tical companies.
I have discussed the data sample, data sources,
and variable definitions of my empirical analysis.
My sample includes 66 Japanese firms which are
active in the pharmaceutical industry, 37 of which
have undertaken foreign R&D activities. The data
are primarily archival, supplemented by surveys
and interviews. The dependent variables are the
types of the first and subsequent foreign R&D
activity that the firms undertook. The independent
variables are the firm’s domestic research capa-
bility, complementary technical skills, and time
of first activity, plus the firm’s foreign market
presence.
RESULTS
I use nonparametric analysis to test the hypoth-
eses. The sample size reduces from 66 firms to
37 when I include only the firms that undertook
international R&D activities. The 37 firms include
20 established pharmaceutical firms and 17 recent
entrants. The small numbers involved here pre-
clude the use of complex statistical techniques.
Hypothesis 1 predicted that firms will tend to
undertake foreign research in a sequence of spon-
sored, collaborative, and controlled research
activities. Tables 3a–c report the actual
sequences. Contrary to the prediction, most
pharmaceutical firms do not follow the strict pre-
dicted sequence. Table 3a shows that 15 of 20
established pharmaceutical companies that under-
took foreign research began with either collabo-
rative (10 cases) or controlled (5 cases) activities
first, rather than with sponsored research (5
cases). Table 3b shows that among the five estab-
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lished pharmaceutical firms that began with spon-
sored foreign research, two undertook no other
subsequent forms of research activity, while two
next undertook collaborative relationships and one
jumped directly to controlled activities. Some
support for a modified sequence does appear in
Table 3c, which reports the second type of
activity given that the first was collaborative.
Of the 10 established pharmaceutical firms that
established collaborative activities first, five had
no further activities or only additional collabo-
rative activities, two established sponsored activi-
ties subsequently, and three moved on to con-
trolled activities. This means that 8 of the 10
firms remained in the modified sequence, which is
a statistically significant result (p = 0.055) using a
binomial test (Wonnacott and Wonnacott, 1977).
Thus, the results reject the overall sequence for
established pharmaceutical companies, but pro-
vide moderate support for an intermediate
sequence that begins with collaboration and pro-
ceeds to controlled activities.
By contrast to the results concerning estab-
lished pharmaceutical firms, Tables 3a–c provide
greater support for Hypothesis 1 with respect to
recent entrants to the industry. Table 3a shows
that recent entrants are more likely to begin with
sponsored research, which occurred in 11 of 17
cases (65%), while four began with collaboration,
and only two began immediately with controlled
research. Table 3b shows that the sequence for
the firms that began with sponsored research is
mixed thereafter, with two of the 11 undertaking
collaborative research next, four jumping directly
t controlled activities as a next step, and five
undertaking no additional forms of research
activity. In the modified sequence reported in
Table 3c, of the four recent entrants that began
with collaborative activities, one next undertook
controlled activities and the other three undertook
no other forms of research activities. Thus, there
is some support for the initial sponsorship stage
in the sequence for recent entrants to the industry
and for sequential expansion by firms that initially
undertake collaborative research.
Three general conclusions concerning research
sequences stand out in the tables. First, few firms
jumped directly to controlled research (only 7 of
37= 19%; Table 3a). Second, most established
pharmaceutical firms that undertook foreign
research were able to take an immediate organi-
zational presence, most often through collabo-
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Table 3a. Mode of initial foreign R&D activity
Number of firms Number of firms
Number of firms with sponsored with collaborative Number of
Number of firms with international activity as first activity as first controlled activity
Type of firm in sample R&D activities activity activity as first activities
Pharmaceutical 31 20 5 10 5
New entrants 35 17 11 4 2
Total 66 37 16 14 7
Table 3b. Second type of entry given that first entry was sponsored (column 3, Table 1)
No other type of entry
(either no new entry or only
Type of firm Number of firms additional sponsored activities) Collaborative Controlled
Pharmaceutical 5 2 2 1
New entrants 11 5 2 4
Total 16 7 4 5
Table 3c. Second type of entry given that first entry was collaborative (column 4 of Table 1)
No other type of entry
(either no new entry or only
additional collaborative
Type of firm Number of firms activities) Sponsored Controlled
Pharmaceutical 10 5 2 3
New entrants 4 3 0 1
Total 14 8 2 4
rative relationships, while many recent entrants
to the industry needed to begin with sponsored
research. Third, many of the firms that expanded
after beginning with an initial sponsorship entry
jumped directly to controlled research (five of
nine = 56%; Table 3b). These conclusions have
intriguing implications for understanding the dif-
fering pressures between learning and protection.
The results offer a revised interpretation of the
learning argument concerning foreign R&D. That
is, few firms possess enough knowledge of
another country’s research environment to jump
directly to controlled research as a first activity.
However, firms with established presence in an
industry often possess enough relevant knowledge
to pick foreign partners with which to undertake
initial collaborative research. Firms with little
industry experience, however, are more likely to
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need an initial period of sponsoring research. This
suggests that knowledge of the industry and the
technology often dominates knowledge of the
broader national environment in explaining initial
entry modes. After an initial sponsorship or
collaborative activity, moreover, many firms move
to controlled research. Thus, once firms gain
i itial knowledge of the research environment,
concern for controlling research and protecting
proprietary rights often comes to the fore. None-
theless, it is notable that less than half of the firms
that have undertaken foreign research activities in
the sample had advanced to controlled activities
by the end of the study period (16 of 37= 43%;
Tables 3a–c). Clearly, the learning opportunities
that sponsorship and collaboration provide offer
strong incentives for foreign research.
These results echo Pisano’s (1989) results in
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his study of the biotechnology industry. He noted
that in the early years of the industry virtually
all biotechnological innovation took place through
collaborative arrangements between biotechno-
logy firms and established pharmaceutical firms.
These arrangements were collaborative initially
because of the complementary nature of the skills
provided by biotechnological firms and the
pharmaceutical firms. Due to transactions costs
associated with these collaborative efforts and
the organizational history of established firms,
however, vertical integration became more likely.
Pisano’s results suggested that firms with more
previous R&D experience in the relevant biotech-
nology were more likely to internalize new
biotechnology R&D projects. There is some indi-
cation that we are seeing some of this internali-
zation as some of the Japanese pharmaceutical
firms move to controlled research activities.
Hypothesis 2 predicted that firms with strong
scientific knowledge capabilities would often
undertake a foreign collaborative or controlled
research activity before undertaking a sponsored
research activity. Domestic research capability is
the first measure of scientific knowledge capabili-
ties. The results in Table 4a provide moderate
support for this prediction for established pharma-
ceutical firms with respect to domestic R&D
skills. Among firms with the greatest number of
drug patents, only one of seven (14%) began
with sponsored research. By contrast, among
firms with low to medium numbers of drug pat-
ents, 4 of 13 (31%) began with sponsored
research. Thus, although few established pharma-
ceutical companies began with sponsored
research, the results also show that the firms that
did begin with sponsored research rarely had
strong domestic research capabilities.
Table 4a. Pharmaceutical firms mode of foreign R&D by drug patents
Total number No foreign Sponsored Collaborative Controlled foreign
of firms R&D Foreign R&D foreign R&D foreign R&D R&D
Low drug
patents 11 8 3 0 2 1
Med. drug
patents 12 2 10 4 4 2
High drug
patents 8 1 7 1 4 2
Note: Drug patent categories were determined by ranking the firms by number of patents and breaking the sample at logical
break points. Low patents were 0–3 drug patents, medium were 6–19 and high were 21–118 during the period 1975–80.
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The results in Table 4b provide no support for
Hypothesis 2 with respect to recent entrants to
the pharmaceutical industry. As Table 3a reported
earlier, most such firms began with sponsored
research. Among those that began with collabo-
rative or controlled research, there is no relation-
ship with greater numbers of drug patents. I will
discuss the contrast between the results for the
established pharmaceutical firms and the recent
entrants after presenting the other results.
Complementary technical skills are the second
measure of scientific knowledge capabilities.
Hypothesis 2 predicted that firms with strong
scientific knowledge capabilities would establish
a collaborative or controlled foreign R&D activity
first. Table 5a provides moderate support for the
prediction with respect to complementary techni-
skills. The table shows that initial entry via
sponsorship declines markedly from low
(2/3 = 67%) to medium (1/5= 20%) fermentation
patents, and then declines slightly further to the
high fermentation patent category (2/12= 17%).
Thus, firms with stronger complementary techni-
cal skills were more likely to establish collabo-
rative or controlled foreign research activities
first.
The results in Table 5b provide no support for
Hypothesis 2 for recent entrants to the pharma-
ceutical industry with regard to complementary
technical skills. As Table 3a reported earlier, most
such firms began with sponsored research. As in
the case of drug patents, there is no relationship
between greater numbers of fermentation patents
nd initial collaborative or controlled research.
Alternative explanations for the sequence of
entry predicted that firms that started their foreign
R&D activities later in the study period would be
more likely to establish collaborative or controlled
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Table 4b. New entrants mode of foreign R&D activity by drug patents
Total number No foreign Sponsored Collaborative Controlled foreign
of firms R&D Foreign R&D foreign R&D foreign R&D R&D
Low drug
patents 20 11 9 6 1 2
Med. drug
patents 7 4 3 1 2 0
High drug
patents 8 3 5 4 1 0
Note: The patent categories were determined by ranking the firms by number of drug patents and breaking the sample at
logical break points; for this table, low patents were 0 patents, medium were 1–4 and high were 8–64 during the period
1975–80.
Table 5a. Pharmaceutical firms mode of foreign R&D by fermentation patents
Total number No foreign Sponsored Collaborative Controlled foreign
of firms R&D Foreign R&D foreign R&D foreign R&D R&D
Low patents 9 6 3 2 0 1
Medium
patents 9 4 5 1 3 1
High patents 13 1 12 2 7 3
Note: The fermentation patent categories were determined by ranking the firms by number of patents and breaking the sample
into thirds unless thre was no significant difference between the firms on either side of the break point. In this table, low
patents corresponds to 0 patents, medium to 1–3 patents and high to 5–39 patents.
Table 5b. New entrants mode of foreign R&D activity by fermentation patents
Total number No foreign Sponsored Collaborative Controlled foreign
of firms R&D Foreign R&D foreign R&D foreign R&D R&D
Low patents 17 10 7 4 2 1
Medium
patents 10 3 7 5 1 1
High patents 8 5 3 2 1 0
Note: The patent categories were determined by ranking the firms by number of patents and breaking the sample into thirds
unless there was no significant difference between the firms on either side of the break point. In this table, low patents
corresponds to 0 patents, medium to 1–3 patents and high to 7–56 patents.
activities first. Table 1 provides moderate support
for the prediction with respect to established
pharmaceutical firms. During the first 3 years, 4
of 7 (57%) cases involved collaborative or con-
trolled research, compared with 11 of 13 (85%)
cases during the last 9 years of the study period.
The results in Table 1 do not support the predic-
tion for recent entrants, however, as there is
no increasing tendency toward collaborative or
controlled research among these firms.
The second alternative explanation predicted
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that firms with experience in the foreign market
would be more likely to establish collaborative
or controlled activities out of sequence. The cor-
relations in Table 2 do not support such a predic-
tion. In fact, the correlations in Table 2 indicate
that pharmaceutical firms with higher export
ratios were more likely to establish sponsored
nternational R&D activities.
Comparing the results concerning Hypothesis 2
with respect to established pharmaceutical firms
and recent entrants provides useful insights con-
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cerning the importance of environmental knowl-
edge. Established pharmaceutical firms are some-
what more likely to undertake initial collaborative
or controlled research if they have strong do-
mestic research capabilities and complementary
technical skills, and if they are later to initiate
foreign research. Thus, their own strength, along
with the competitive threats and learning oppor-
tunities that other firms create, appear to influence
the choices of the established firms. By contrast,
the research capabilities, complementary technical
skills, and entry timing had no influence on initial
entry mode choices by recent entrants to the
pharmaceutical industry. Instead, at all skill levels
and throughout the study period, most recent
entrants preferred sponsorships as their first for-
eign research activity. The comparison again
speaks to the importance of the differential
knowledge of the industry environment held by
established firms and recent entrants. The differ-
ential capabilities and prior expansion by com-
petitors likely influence the established firms most
strongly because the established firms have
enough understanding of the pharmaceutical
industry environment to be able to take those
factors into account. For the recent entrants, by
contrast, the lack of knowledge of the industry
environment is the dominant factor. Only once
they obtain more knowledge of the pharmaceu-
tical research environment can most firms begin
to consider collaborative or controlled research
activities.
There is another factor that might affect the
new entrant firm’s choice of entry mode. In
addition to their lack of knowledge of the industry
environment there is also the fact that potential
partners will be unfamiliar with the new entrant
companies. Prospective partners may be reluctant
to enter into collaborative arrangements with
unknown quantities such as the new entrants.
Once the new entrants have demonstrated their
commitment and perhaps their capabilities in the
new technological area, they may become more
attractive to firms seeking partnerships beyond
the purely financial.
Sensitivity analysis concerning the influence of
foreign sales offices on the choice of initial
research mode reinforces the implications con-
cerning the importance of knowledge of the
research environment. I found little or no differ-
ence in initial foreign research mode based on
the presence of foreign sales offices, either among
 1998 John Wiley & Sons, Ltd. Strat. Mgmt. J., Vol. 19, 149–168 (1998)
established pharmaceutical firms or recent
entrants. This null result suggests that knowledge
of the research environment is a more important
factor than knowledge of the market environment
in its influence on foreign research activities.
DISCUSSION
The analysis of mode and sequence of establish-
ment of foreign R&D activities by Japanese firms
offered mixed support for the hypotheses
developed in this work. There is some evidence
of a sequence of modes used by the firms estab-
lishing foreign R&D activities. However, this
sequence may not start with the initial step of
sponsored research as is demonstrated by the
pharmaceutical firms. Instead, the majority of the
pharmaceutical firms initiated foreign R&D with
collaborative arrangements.
The results suggest two other hypotheses. One
is, that firms that enter a new technological
r gime, complementary to their existing business,
will be more likely to initially establish collabo-
rative foreign R&D activities than other types of
activities. A collaborative arrangement is the most
organizationally interdependent arrangement
which firms will enter into if they see a longer-
term benefit to be derived from the activity
(Hagedoorn, 1993). Pisano (1990) found that
firms that were more dependent on pharmaceu-
tical sales were more likely to internalize biotech-
nology R&D. Pisano’s analysis included multiple
biotechnology projects for each firm, not just the
initial activity, so it is possible that the sum of
all current and future biotechnology projects for
firms in my sample could indicate a propensity
to internalize. I argue that when the technology
is both new and closely related to the firm’s
traditional activity, the firm is more likely to
initiate a collaborative venture.
In contrast to the traditional pharmaceutical
firms, the new entrants to the pharmaceutical
industry appeared to be far more likely to estab-
lish sponsored activities initially. This may be
explained by the fact that new entrant firms would
be less dependent on pharmaceutical sales than
traditional pharmaceutical firms. It may also indi-
cate a fundamentally different motivation for
entering into an international R&D activity. New
entrants to the pharmaceutical industry are look-
ing for growth opportunities by applying existing
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skills to new lines of business. This closely fol-
lows Penrose’s (1959) argument that firms often
grow by using intangible skills in new businesses.
These business opportunities present themselves
as a result of the new entrant firm’s activities in
the markets where the complementary technical
opportunities emerge.
In this paper I have explored the question of
entry mode and sequence in international R&D
activities. My study has broadened the discussion
of foreign R&D entry modes to include the
impact of a firm’s existing capabilities and its
knowledge of the industry environment on its
choice of entry mode and sequence. The analysis
of both incumbents and new entrants in the
pharmaceutical industry demonstrates how their
different capabilities and levels of industry knowl-
edge influence their choice of entry mode. This
finding has implications for understanding the
motivations of the various players in an industry
as well as for participants in R&D seeking fund-
ing and/or partners.
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